Share this article
Share this article
SAN DIEGO, April 6, 2021 /PRNewswire/ NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the NuVasive Simplify
® Cervical Artificial Disc (Simplify Disc) received approval from the U.S. Food and Drug Administration (FDA) for two-level cervical total disc replacement (cTDR). This approval is an incredible achievement for the Simplify Disc and further broadens the growth opportunities for the NuVasive C360 portfolio, said Massimo Calafiore, executive vice president, Global Business Units at NuVasive. There is immense surgeon excitement for this latest edition to our cervical offering, and the expanded two-level indication provides greater opportunities to bring the most clinically effective technology in the cTDR market to more patients.
NuVasive s Simplify Disc Receives FDA Approval for Two-Level Cervical Total Disc Replacement streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NuVasive Acquires Simplify Medical
Simplify Cervical Artificial Disc provides NuVasive most clinically effective technology in the cervical total disc replacement (cTDR) procedure segment
Expands growth opportunities and further differentiates Company s comprehensive portfolio across ACDF, PCF, and cTDR procedures
News provided by
Share this article
Share this article
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that it has acquired Simplify Medical, a privately held company and developer of the Simplify
® Cervical Artificial Disc (Simplify Disc) for cervical total disc replacement (cTDR).